Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4.
Asiedu, M. K., F. D. Beauchamp-Perez, J. N. Ingle, M. D. Behrens, D. C. Radisky & K. L. Knutson (2014) AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene, 33, 1316-24.
Sun, Y., X. Wang, Q. Zhou, Y. Lu, H. Zhang, Q. Chen, M. Zhao & S. Su (2015) Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol Rep, 33, 338-46.
Liu, Q., J. Hodge, J. Wang, Y. Wang, L. Wang, U. Singh, Y. Li, Y. Yao, D. Wang, W. Ai, P. Nagarkatti, H. Chen, P. Xu, E. A. Murphy & D. Fan (2020) Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation. Theranostics, 10, 8365-8381.
Lu, J., Y. Xu, X. Wei, Z. Zhao, J. Xue & P. Liu (2016) Emodin Inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer Cells via ILK/GSK-3β/Slug Signaling Pathway. Biomed Res Int, 2016, 6253280.
Gu, J., C. F. Cui, L. Yang, L. Wang & X. H. Jiang (2019) Emodin Inhibits Colon Cancer Cell Invasion and Migration by Suppressing Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Pathway. Oncol Res, 27, 193-202.
Fu, J. M., J. Zhou, J. Shi, J. S. Xie, L. Huang, A. Y. Yip, W. T. Loo, L. W. Chow & E. L. Ng (2012) Emodin affects ERCC1 expression in breast cancer cells. J Transl Med, 10 Suppl 1, S7.
Song, X., X. Zhou, Y. Qin, J. Yang, Y. Wang, Z. Sun, K. Yu, S. Zhang & S. Liu (2018) Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes. Int J Mol Med, 42, 579-588.
Li, W., H. Zhang, Y. G. Assaraf, K. Zhao, X. Xu, J. Xie, D. H. Yang & Z. S. Chen (2016) Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat, 27, 14-29.
Markman, J. L., A. Rekechenetskiy, E. Holler & J. Y. Ljubimova (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev, 65, 1866-79.
Kalyane, D., N. Raval, R. Maheshwari, V. Tambe, K. Kalia & R. K. Tekade (2019) Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl, 98, 1252-1276.
Jain, V., H. Kumar, H. V. Anod, P. Chand, N. V. Gupta, S. Dey & S. S. Kesharwani (2020) A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Control Release, 326, 628-647.
Mukerjee, A., A. P. Ranjan & J. K. Vishwanatha (2012) Combinatorial nanoparticles for cancer diagnosis and therapy. Curr Med Chem, 19, 3714-21.
Jiang, Z. S., Y. Z. Sun, S. M. Wang & J. S. Ruan (2017) Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer, 8, 2319-2327.
Du, B. & J. S. Shim (2016) Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules, 21.
Li, S., Y. Fan, A. Kumagai, E. Kawakita, M. Kitada, K. Kanasaki & D. Koya (2020b) Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells. Int J Mol Sci, 21.
Xu, J., S. Lamouille & R. Derynck (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res, 19, 156-72.
Rodón, J., M. Carducci, J. M. Sepulveda-Sánchez, A. Azaro, E. Calvo, J. Seoane, I. Braña, E. Sicart, I. Gueorguieva, A. Cleverly, N. S. Pillay, D. Desaiah, S. T. Estrem, L. Paz-Ares, M. Holdhoff, J. Blakeley, M. M. Lahn & J. Baselga (2015) Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs, 33, 357-70.
Gu, M., W. Zheng, M. Zhang, X. Dong, Y. Zhao, S. Wang, H. Jiang & X. Zheng (2020) LncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through p-CREB/Bcl-2 apoptosis signaling pathway in breast cancer. J Cancer, 11, 3645-3654.
Song, X., X. Zhou, Y. Qin, J. Yang, Y. Wang, Z. Sun, K. Yu, S. Zhang & S. Liu (2018) Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes. Int J Mol Med, 42, 579-588.
Wang, S., T. Chen, R. Chen, Y. Hu, M. Chen & Y. Wang (2012) Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm, 430, 238-46.
Tahir, N., A. Madni, A. Correia, M. Rehman, V. Balasubramanian, M. M. Khan & H. A. Santos (2019) Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy. Int J Nanomedicine, 14, 4961-4974.